A Phase 1/2 interventional study of GDX012 and Chemotherapy Agents in Leukemia, sponsored by Takeda. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Takeda · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leukemia, Myeloid, Acute by Takeda — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Takeda.
Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 14th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 14 studies in Leukemia, Myeloid, Acute by Takeda is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 5 · Phase 3 2
First in 1997; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 60 across the 13 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
The drug being tested in this study is called GDX012. GDX012 is being tested to evaluate the safety and tolerability in adult participants with AML.
The study will enroll approximately 53 patients in two phases, dose escalation and dose expansion.
During Phase 1 (sequential dose escalation), participants will be assigned to one of the following treatment groups each consisting of 3 to 6 participants to receive GDX012 at one of the three dose levels:
Upon completion of Phase 1, 1 to 2 dose levels will be selected for Phase 2a of the study. At the completion of Phase 2a of the study a single dose may be selected by the sponsor and investigators as the recommended phase 2 dose (RP2D) for future study.
This multi-center trial will be conducted in the United States and Japan. The overall time to participate in the study is approximately 14 months.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
This study's enrollment of 16 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have confirmed acute myeloid leukemia (R/R AML) including:
i. Two courses of intensive induction chemotherapy. ii. At least 2 cycles of hypomethylating agent (HMA) or low-dose, cytarabine-based combination regimen.
iii. At least 4 cycles of HMA monotherapy.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GDX012 weight-based dose level 1 as an intravenous (IV) infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 1 was the lowest dose level.
Drug: GDX012 · Drug: Chemotherapy Agents
Participants received GDX012 weight-based dose level 2 as an IV infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 2 was higher than Dose Level 1.
Drug: GDX012 · Drug: Chemotherapy Agents
Participants received GDX012 weight-based dose level 3 as an IV infusion on Day 1 of Phase 1, following lymphodepleting chemotherapy. Dose Level 3 was higher than Dose Level 2.
Drug: GDX012 · Drug: Chemotherapy Agents
GDX012 suspension for IV infusion.
Also known as: TAK-012
Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
Number of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012
DLTs were defined as events occurring by Day 30 after the first GDX012 infusion considered related to GDX012 if they could not be explained by underlying disease, prior therapy, intercurrent illness, or lymphodepleting chemotherapy. Events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. DLTs included severe non-hematologic toxicities (Grade 3-4, unresolved or involving vital organs), Grade ≥3 graft versus host disease (GvHD) graded per the Mount Sinai Acute GvHD International Consortium recommendations and 2014 National Institutes of Health (NIH) Consensus, Grade 3-4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy (ASTCT) criteria, Grade ≥3 infusion reactions or tumor lysis syndrome (TLS), persistent cytopenia or marrow hypocellularity, and any Grade 5 toxicity attributable to GDX012.
Time frame: Up to 30 days post infusion
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event or a previous condition that has increased in severity or frequency since the administration of study drug. TEAEs are defined as any AE that begins on or after the initiation of treatment with a study intervention or any existing event that worsens following exposure to the study intervention.
Time frame: Up to 14 months
Percentage of Participants With Disease Response
Percentage of participants with disease response included participants who achieved complete response (CR), complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), based on responses assessed by the investigator according to the 2022 European Leukemia Net \[ELN\] response criteria for acute myeloid leukemia (AML). CR was defined as the sum of complete remission and complete remission without measurable residual disease (MRD). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-.
Time frame: Up to 14 months
Percentage of Participants With Measurable Residual Disease (MRD) Negative Status as Determined by Flow Cytometry
The MRD negative status was defined as (less than) \<0.1% detectable disease based on local assessment of bone marrow and/or blood.
Time frame: Up to 14 months
Duration of Response (DOR)
DOR was planned to be assessed for participants with CR, CRh, or CRi and was defined as the time from the date of first documented CR, CRh, or CRi to the date of first documented relapse or death from any cause, whichever comes first. CR was defined as the sum of Complete Remission and Complete Remission without MRD. CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD- .
Time frame: Up to 14 months
Event-free Survival (EFS)
EFS was defined as the time from the date of the first GDX012 administration to the date of treatment failure, relapse for those who achieved CR, CRh, or CRi, or death from any cause, whichever came first. CR was defined as the sum of Complete Remission and Complete Remission without MRD (CRMRD-). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-. EFS was analyzed using the Kaplan-Meier method.
Time frame: Up to 14 months
Overall Survival (OS)
OS was defined as the time from the date of the first GDX012 administration to the date of death from any cause. Participants without documentation of death at the time of analysis were censored at the last contact date. OS was analyzed using the Kaplan-Meier method.
Time frame: Up to 14 months
Participants took part in the study at 10 investigative sites in United States and Japan from 11 July 2023 to 30 November 2025.
| Milestone | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Started | 4 | 4 | 8 |
| Completed | 0 | 0 | 0 |
| Not completed | 4 | 4 | 8 |
| Withdrew: Death | 1 | 2 | 7 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Reason not specified | 1 | 2 | 0 |
DLTs were defined as events occurring by Day 30 after the first GDX012 infusion considered related to GDX012 if they could not be explained by underlying disease, prior therapy, intercurrent illness, or lymphodepleting chemotherapy. Events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. DLTs included severe non-hematologic toxicities (Grade 3-4, unresolved or involving vital organs), Grade ≥3 graft versus host disease (GvHD) graded per the Mount Sinai Acute GvHD International Consortium recommendations and 2014 National Institutes of Health (NIH) Consensus, Grade 3-4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy (ASTCT) criteria, Grade ≥3 infusion reactions or tumor lysis syndrome (TLS), persistent cytopenia or marrow hypocellularity, and any Grade 5 toxicity attributable to GDX012.
| Participants | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) to Determine the Maximum Tolerated Dose (MTD) of GDX012 | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event or a previous condition that has increased in severity or frequency since the administration of study drug. TEAEs are defined as any AE that begins on or after the initiation of treatment with a study intervention or any existing event that worsens following exposure to the study intervention.
| Participants | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 3 | 3 | 8 |
Percentage of participants with disease response included participants who achieved complete response (CR), complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), based on responses assessed by the investigator according to the 2022 European Leukemia Net \[ELN\] response criteria for acute myeloid leukemia (AML). CR was defined as the sum of complete remission and complete remission without measurable residual disease (MRD). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-.
| percentage of participants | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| CR | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
| CRh | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
| CRi | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
The MRD negative status was defined as (less than) \<0.1% detectable disease based on local assessment of bone marrow and/or blood.
| percentage of participants | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Complete Remission without MRD | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
| Complete Remission with Partial Hematologic Recovery without MRD | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
| Complete Remission with Incomplete Hematologic Recovery without MRD | 0 (0.0 to 70.8) | 0 (0.0 to 70.8) | 0 (0.0 to 45.9) |
DOR was planned to be assessed for participants with CR, CRh, or CRi and was defined as the time from the date of first documented CR, CRh, or CRi to the date of first documented relapse or death from any cause, whichever comes first. CR was defined as the sum of Complete Remission and Complete Remission without MRD. CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD- .
No measurements were reported for this outcome.
EFS was defined as the time from the date of the first GDX012 administration to the date of treatment failure, relapse for those who achieved CR, CRh, or CRi, or death from any cause, whichever came first. CR was defined as the sum of Complete Remission and Complete Remission without MRD (CRMRD-). CRh was defined as the sum of CRh and CRhMRD-. CRi was defined as the sum of CRi and CRiMRD-. EFS was analyzed using the Kaplan-Meier method.
| months | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Event-free Survival (EFS) | 0.033 (NA to NA) | 0.033 (0.033 to NA) | 0.033 (NA to NA) |
OS was defined as the time from the date of the first GDX012 administration to the date of death from any cause. Participants without documentation of death at the time of analysis were censored at the last contact date. OS was analyzed using the Kaplan-Meier method.
| months | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Overall Survival (OS) | 5.618 (NA to NA) | 6.045 (3.154 to NA) | 3.121 (0.723 to 5.947) |
Collected over Up to 14 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Dose Escalation of GDX012 (Dose Level 1) | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1: Dose Escalation of GDX012 (Dose Level 2) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1: Dose Escalation of GDX012 (Dose Level 3) | 7/8 (87.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Event | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| Acute graft versus host diseaseImmune system disorders | 0/3 | 1/3 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 1/8 |
| HypervolaemiaMetabolism and nutrition disorders | 1/3 | 0/3 | 0/8 |
| PneumoniaInfections and infestations | 1/3 | 0/3 | 0/8 |
| SepsisInfections and infestations | 1/3 | 1/3 | 0/8 |
| Immune effector cell-associated neurotoxicity syndromeNervous system disorders | 0/3 | 0/3 | 1/8 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/8 |
| SinusitisInfections and infestations | 0/3 | 0/3 | 1/8 |
| Event | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/3 | 0/3 | 0/8 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 2/3 | 2/8 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/3 | 2/3 | 0/8 |
| ChillsGeneral disorders | 1/3 | 0/3 | 4/8 |
| Cytokine release syndromeImmune system disorders | 0/3 | 1/3 | 4/8 |
| FatigueGeneral disorders | 1/3 | 1/3 | 4/8 |
| NauseaGastrointestinal disorders | 1/3 | 1/3 | 4/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 3/8 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/3 | 1/3 | 3/8 |
| Abdominal painGastrointestinal disorders | 1/3 | 0/3 | 0/8 |
Intent-to-Treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) | Total |
|---|---|---|---|---|
| Mean | 62.8 ± 14.57 | 59.3 ± 21.64 | 62.5 ± 10.56 | 61.8 ± 13.8 |
| Sex: Female, Male(Participants) | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) | Total |
|---|---|---|---|---|
| Female | 4 | 1 | 3 | 8 |
| Male | 0 | 3 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 4 | 8 | 15 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Phase 1: Dose Escalation of GDX012 (Dose Level 1) | Phase 1: Dose Escalation of GDX012 (Dose Level 2) | Phase 1: Dose Escalation of GDX012 (Dose Level 3) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 2 | 4 | 7 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Aug 2025, 25 months.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.